According to Agilent CEO Mike McMullen, drivers of the company’s growth during its Fiscal Year 2021 have included the Diagnostics and Genomics Group (DGG), the revival of its pathology business, an increase in companion diagnostic activity, and the acquisition of Resolution Biosciences. But while the company has projected revenue growth of between five and a half and seven percent for the current fiscal year, COVID-19 related testing represents a potential headwind to that growth . . .
See More on the Edge
Continue reading this article and more
with a GEN Edge subscription
The post Agilent CEO Talks Diagnostics, Genomics, and 2022 Headwinds appeared first on GEN – Genetic Engineering and Biotechnology News.
